BBOT insider transaction filings
BridgeBio Oncology Therapeutics, Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-06. Screen BBOT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Elmelech Idan — COO & Principal Financial Ofcr | Tax withholding (F): 343 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Ben Yong — Chief Med & Dev Officer | Tax withholding (F): 1,047 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Beltran Pedro — President and CEO, Director | Tax withholding (F): 1,047 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Cobo Marc — Principal Accounting Officer | Tax withholding (F): 125 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Chen Bihua — Director, 10% owner | Other (J): 4,528,186 @ $0 · Other (J): 2,692,459 @ $0 · Other (J): 1,704,862 @ $0 · Other (J): 130,865 @ $0 | EDGAR |
| 2026-06-18 | 4 | Lebowitz Peter F — Director | Grant/award (A): 7,289 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Kelleher Raymond J. — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Tipirneni Praveen P. — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Kumar Neil — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Bauer Jake — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Chen Bihua — Director, 10% owner | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | MCCORMICK FRANK — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Elmelech Idan — COO & Principal Financial Ofcr | Grant/award (A): 758,222 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Beltran Pedro — President and CEO, Director | Grant/award (A): 1,103,837 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Ben Yong — Chief Med & Dev Officer | Tax withholding (F): 1,047 @ $9.03 | EDGAR |
| 2026-05-05 | 4 | Beltran Pedro — President and CEO, Director | Tax withholding (F): 1,047 @ $9.03 | EDGAR |
| 2026-05-05 | 4 | Mehra Uneek | Tax withholding (F): 524 @ $9.03 | EDGAR |
| 2026-03-26 | 4 | Lebowitz Peter F — Director | Grant/award (A): 63,350 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Mehra Uneek — Chief Financial Officer | Grant/award (A): 23,330 @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Beltran Pedro — Chief Scientific Officer | Grant/award (A): 46,670 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Ben Yong — Chief Med & Dev Officer | Grant/award (A): 46,670 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 1,114,400 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Disposition to issuer (D): 1,114,400 (derivative) | EDGAR |
| 2025-10-16 | 4 | BridgeBio Pharma LLC — 10% owner BridgeBio Pharma, Inc. — 10% owner | Other (J): 784,720 | EDGAR |
| 2025-10-06 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 1,614,400 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Beltran Pedro — Chief Scientific Officer | Grant/award (A): 357,177 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Ben Yong — Chief Med & Dev Officer | Grant/award (A): 357,177 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Mehra Uneek — Chief Financial Officer | Grant/award (A): 633,570 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Tipirneni Praveen P. — Director | Grant/award (A): 52,269 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 499,731 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Bauer Jake — Director | Grant/award (A): 138,193 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | MCCORMICK FRANK — Director | Grant/award (A): 91,076 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Chen Bihua — Director, 10% owner | Option exercise (M): 4,172,126 · Disposition to issuer (D): 152,940 @ $0 · Grant/award (A): 760,496 @ $10.72 · Grant/award (A): 639,110 @ $10.72 · Grant/award (A): 5,598,425 @ $10.72 · Grant/award (A): 1,905,046 · +4 more | EDGAR |
| 2025-08-11 | 4 | Obradovic Nebojsa — Chief Legal Officer | Holdings only — no transactions reported | EDGAR |
| 2025-08-11 | 4 | Tripp Caleb — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2025-08-11 | 4 | Holman Albert A III | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | McKenna Mark C. | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Schmid John P. | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — BridgeBio Oncology Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 4.01 — Changes in Registrant's Certifying Accountant 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.05 — Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics 5.06 — Change in Shell Company Status 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BBOT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →